Evidence map›Paper›PMID 32546053›Full record

ArticleTissue engineering. Part A2021

Combined Hydrogel and Mesenchymal Stem Cell Therapy for Moderate-Severity Disc Degeneration in Goats.

Chenghao Zhang, Sarah E Gullbrand, Thomas P Schaer, Sophie Boorman, Dawn M Elliott, Weiliam Chen, George R Dodge, Robert L Mauck, Neil R Malhotra, Lachlan J Smith

Open access · greenAbstract read
In one paragraph

Article in Tissue engineering. Part A, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Intervertebral disc degeneration.Nature reviews. Disease primers · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Chenghao ZhangTranslational Musculoskeletal Research Center, Corporal Michael J. Crescenz Philadelphia VA Medical Center, Philadelphia, Pennsylvania, USA.
Sarah E GullbrandTranslational Musculoskeletal Research Center, Corporal Michael J. Crescenz Philadelphia VA Medical Center, Philadelphia, Pennsylvania, USA.
Thomas P SchaerComparative Orthopaedic Research Laboratory, New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, Pennsylvania, USA.
Sophie BoormanComparative Orthopaedic Research Laboratory, New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, Pennsylvania, USA.
Dawn M ElliottDepartment of Biomedical Engineering, University of Delaware, Newark, Delaware, USA.
Weiliam ChenDepartment of Surgery, New York University School of Medicine, New York, New York, USA.
George R DodgeTranslational Musculoskeletal Research Center, Corporal Michael J. Crescenz Philadelphia VA Medical Center, Philadelphia, Pennsylvania, USA.
Robert L MauckTranslational Musculoskeletal Research Center, Corporal Michael J. Crescenz Philadelphia VA Medical Center, Philadelphia, Pennsylvania, USA.
Neil R MalhotraTranslational Musculoskeletal Research Center, Corporal Michael J. Crescenz Philadelphia VA Medical Center, Philadelphia, Pennsylvania, USA.
Lachlan J SmithTranslational Musculoskeletal Research Center, Corporal Michael J. Crescenz Philadelphia VA Medical Center, Philadelphia, Pennsylvania, USA.
Philadelphia VA Medical Center · USUniversity of Pennsylvania · USNew York University · USUniversity of Delaware · US

Funding

Overall: Resource-based Center for Musculoskeletal Disorders Research (Overall Application)P30AR069619 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI LOUIS J SOSLOWSKY · 2016 to 2026
$9.1M
Pathogenesis and Treatment of Bone Disease in the MucopolysaccharidosesR01AR071975 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI SMITH, LACHLAN JAMES · 2017 to 2021
$1.9M
Regenerative potential of embryonic notochordal nucleus pulposus progenitorsR21AR070959 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI MALHOTRA, NEIL, SMITH, LACHLAN JAMES · 2017 to 2018
$401k
Bioactive Injectable Implants for Functional Intervertebral Disc RegenerationI01RX001321 · VA · PHILADELPHIA VA MEDICAL CENTER · PI Robert L Mauck, Lachlan James Smith · 2014 to 2026
–
NIAMS NIH HHS P30 AR069619NIAMS NIH HHS R01 AR071975NIAMS NIH HHS R21 AR070959RRD VA I01 RX001321
6 · The paper itself

Abstract

Intervertebral disc degeneration is a cascade of cellular, structural, and biomechanical changes that is strongly implicated as a cause of low-back pain. Current treatment strategies have poor long-term efficacy as they seek only to alleviate symptoms without preserving or restoring native tissue structure and function. The objective of this study was to evaluate the efficacy of a combined triple interpenetrating network hydrogel (comprising dextran, chitosan, and teleostean) and mesenchymal stem cell (MSC) therapy targeting moderate-severity disc degeneration in a clinically relevant goat model. Degeneration was induced in lumbar discs of 10 large frame goats by injection of chondroitinase ABC. After 12 weeks, degenerate discs were treated by injection of either hydrogel alone or hydrogel seeded with allogeneic, bone marrow-derived MSCs. Untreated healthy and degenerate discs served as controls, and animals were euthanized 2 weeks after treatment. Discs exhibited a significant loss of disc height 12 weeks after degeneration was induced. Two weeks after treatment, discs that received the combined hydrogel and MSC injection exhibited a significant, 10% improvement in disc height index, as well as improvements in histological condition. Discs that were treated with hydrogel alone exhibited reduced tumor necrosis factor-α expression in the nucleus pulposus (NP). Microcomputed tomography imaging revealed that the hydrogel remained localized to the central NP region of all treated discs after 2 weeks of unrestricted activity. These encouraging findings motivate further, longer term studies of therapeutic efficacy of hydrogel and MSC injections in this large animal model. Impact statement Low-back pain is the leading cause of disability worldwide, and degeneration of the intervertebral discs is considered to be one of the most common reasons for low-back pain. Current treatment strategies focus solely on alleviation of symptoms, and there is a critical need for new treatments that also restore disc structure and function. In this study, using a clinically relevant goat model of moderate-severity disc degeneration, we demonstrate that a combined interpenetrating network hydrogel and mesenchymal stem cell therapy provides acute improvements in disc height, histological condition, and local inflammation.

Indexed as

Intervertebral DiscIntervertebral Disc DegenerationMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsDisease Models, AnimalGoatsHydrogelsX-Ray MicrotomographyHydrogelscaprineintervertebral discnucleus pulposuspreclinicalspinetherapy

Identifiers

PMID32546053
PMCPMC7826444
OpenAlexW3034620987

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.